Atrial Fibrillation study: Apixaban vs Rivaroxaban
Official title Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
ClinicalTrials.gov ID: NCT06953726
What this study is testing
What is Apixaban?
Apixaban is an investigational oral anticoagulant being studied for prevention of stroke in patients with atrial fibrillation. Apixaban is designed to inhibit factor Xa in the blood clotting cascade.
Also referred to as Eliquis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if one drug leads to fewer strokes, major bleeds, or deaths than the other.
- Who it's for
- Adults 65 or older with atrial fibrillation or flutter who are already taking apixaban or rivaroxaban.
- What's involved
- Participants will continue their current medication and their health data will be collected from VA electronic records. No extra visits or tests are required.
- Time commitment
- The study will run for about 7 years, with data gathered automatically from medical records after the first prescription.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 22 and older
You may be able to join if
- Male or female Veteran
- Diagnosis of atrial fibrillation (AF) or atrial flutter (AFL) and currently taking either apixaban or rivaroxaban.
- CHA2DS2-Vasc of 3 or more
- Ability to take oral medication and self-reported willingness to adhere to the prespecified apixaban or rivaroxaban regimen
You likely can't join if
- Current use of oral or injectable anticoagulation, without ability to switch to the assigned study medication
- Another indication for anticoagulation, such as pulmonary embolism
- Contraindication to oral anticoagulation
- Known bleeding diathesis
- Documented current pregnancy or lactation in the EHR or self-reported current pregnancy or lactation
- Known allergic reactions or intolerance to apixaban or rivaroxaban
See the full eligibility criteria
- Male or female Veteran
- Diagnosis of atrial fibrillation (AF) or atrial flutter (AFL) and currently taking either apixaban or rivaroxaban.
- CHA2DS2-Vasc of 3 or more
- Ability to take oral medication and self-reported willingness to adhere to the prespecified apixaban or rivaroxaban regimen
- Current use of oral or injectable anticoagulation, without ability to switch to the assigned study medication
- Another indication for anticoagulation, such as pulmonary embolism
- Contraindication to oral anticoagulation
- Known bleeding diathesis
- Documented current pregnancy or lactation in the EHR or self-reported current pregnancy or lactation
- Known allergic reactions or intolerance to apixaban or rivaroxaban
- Most recent estimated glomerular filtration rate (eGFR) is \< 30 mL/minute/1.73m2. An eGFR result must have been obtained within 18 months before randomization.
- Known mechanical heart valve
- Known moderate-severe mitral stenosis
- Known history of left atrial occlusion, excision, or ligation
- Current or planned use of systemic ritonavir, itraconazole, or ketoconazole (topical use of ketoconazole only is allowed)
- Cardiac or thoracic surgery in the past 3 months
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
- Boston, Massachusetts, United States
- Minneapolis, Minnesota, United States
- Portland, Oregon, United States
- Salt Lake City, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 22 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States; Boston, Massachusetts, United States; Minneapolis, Minnesota, United States; Portland, Oregon, United States; Salt Lake City, Utah, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.